Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$27,000.00

Characterizing Adaptive Immune Responses in Chronic Spontaneous Urticaria

FY 2024-25

Summary
Chronic spontaneous urticaria (CSU) is a condition marked by unprovoked wheals and/or angioedema lasting ≥6 weeks, affecting 1-3% of the population and significantly impairing quality of life. Current evidence suggests that most CSU cases have an autoimmune etiology consisting of either type I hypersensitivity attributable to auto-allergic IgE antibodies or type IIb hypersensitivity ascribed to anti-IgE or anti-IgE receptor (FceRI) IgG autoantibodies. Guideline approved treatments, including second-generation H1-antihistamines (sgAHs) and omalizumab, have limited efficacy, with ~27.8% of severe cases failing to respond, particularly those associated with type IIb disease characterized by low IgE levels and positive basophil histamine release assays. Emerging evidence implicates adaptive cellular immunity, particularly Th1, Th2, and Th9 cytokines, in CSU pathogenesis, but transcriptomic analyses to elucidate immune responses and treatment predictors remain unexplored. This study aims to use RNA sequencing of blood and skin samples from CSU patients and healthy controls to identify immune cell compositions and cytokine signatures associated with disease severity and response to sgAHs, omalizumab, cyclosporine, and dupilumab. Patient data will be analyzed for differentially expressed genes, biological pathways, and immune profiles, with results correlated to clinical metrics such as UAS7 scores. By identifying immune pathways linked to clinical heterogeneity and treatment resistance, this project aims to advance understanding of CSU pathogenesis and inform personalized therapeutic strategies targeting dysregulated pathways like Th2 or Th17 immunity.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
530039
Name
Zhu Catherine K
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing Adaptive Immune Responses in Chronic Spontaneous Urticaria
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adaptive Immune System; Allergy; Autoimmunity; Chronic Spontaneous Urticaria; Chronic Urticaria
Abstract
Chronic spontaneous urticaria (CSU) is a condition marked by unprovoked wheals and/or angioedema lasting ≥6 weeks, affecting 1-3% of the population and significantly impairing quality of life. Current evidence suggests that most CSU cases have an autoimmune etiology consisting of either type I hypersensitivity attributable to auto-allergic IgE antibodies or type IIb hypersensitivity ascribed to anti-IgE or anti-IgE receptor (FceRI) IgG autoantibodies. Guideline approved treatments, including second-generation H1-antihistamines (sgAHs) and omalizumab, have limited efficacy, with ~27.8% of severe cases failing to respond, particularly those associated with type IIb disease characterized by low IgE levels and positive basophil histamine release assays. Emerging evidence implicates adaptive cellular immunity, particularly Th1, Th2, and Th9 cytokines, in CSU pathogenesis, but transcriptomic analyses to elucidate immune responses and treatment predictors remain unexplored. This study aims to use RNA sequencing of blood and skin samples from CSU patients and healthy controls to identify immune cell compositions and cytokine signatures associated with disease severity and response to sgAHs, omalizumab, cyclosporine, and dupilumab. Patient data will be analyzed for differentially expressed genes, biological pathways, and immune profiles, with results correlated to clinical metrics such as UAS7 scores. By identifying immune pathways linked to clinical heterogeneity and treatment resistance, this project aims to advance understanding of CSU pathogenesis and inform personalized therapeutic strategies targeting dysregulated pathways like Th2 or Th17 immunity.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zhu, Catherine K
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~